These results highlight the potential of NAT10‐2023 as a promising therapeutic agent for targeting the NAT10‐SMAD3 regulatory axis in HCC, paving the way for new therapeutic strategies in the management of this aggressive cancer. The gene discussed is SMAD3; the disease is cancer.